微信公众号

官网二维码
中国癌症防治杂志

中国癌症防治杂志 ›› 2018, Vol. 10 ›› Issue (5): 352-355.doi: 10.3969/j.issn.1674-5671.2018.05.02

• 基础研究 • 上一篇    下一篇

KU004抑制人源乳腺癌BT474裸鼠异种移植模型肿瘤生长的作用

  

  1. 江苏食品药品职业技术学院；江苏财经职业技术学院；江苏康缘药业股份有限公司
  • 出版日期:2018-10-25 发布日期:2018-12-12
  • 通讯作者: 王振中 E-amil：wzhzh-nj@163.com
  • 基金资助:

    国家科技重大专项课题资助项目（2013ZX09402203）

KU004 inhibits tumor growth in human breast cancer BT474 nude mouse xenograft model

  • Online:2018-10-25 Published:2018-12-12

PDF (PC)

613

赞

摘要：

目的  探讨KU004对人源乳腺癌BT474裸鼠异种移植模型肿瘤的抑制作用。方法 对60只雌性BALB/c裸鼠接种人源乳腺癌BT474细胞，将肿瘤生长至100~160 mm3的40只裸鼠随机分为模型组（0.5%羟丙基甲基纤维素溶液灌胃）、拉帕替尼组（80 mg/kg 拉帕替尼灌胃）、KU004高剂量组（120 mg/kg KU004灌胃）、KU004中剂量组（80 mg/kg KU004灌胃）、KU004低剂量组（40 mg/kg KU004灌胃），每组8只，每天灌胃1次，连续灌胃21 d。分别于给药前以及给药后1 d、4 d 、7 d 、11 d 、14 d 、17 d 、21 d测量各组裸鼠体重及肿瘤体积，计算相对肿瘤增殖率(T/C)和肿瘤抑制率（inhibition rate，IR）。结果 成功建立人源乳腺癌BT474裸鼠异种移植模型。拉帕替尼组、KU004高剂量组、KU004中剂量组、KU004低剂量组裸鼠体重随给药时间延长变化不大，与模型组比较差异均无统计学意义(P>0.05)。给药期间各给药组TV、RTV均低于与模型组（P<0.01），其中拉帕替尼组与KU004中剂量组TV、RTV比较差异无统计学意义（P>0.05）。拉帕替尼组、KU004高剂量组、KU004中剂量组和KU004低剂量组T/C随给药时间延长逐渐降低，至给药后21 d T/C分别为15.6%、6.9%、11.4%和32.7%， IR分别为85.0%、95.0%、91.0%和67.0%。结论 不同剂量KU004均可对人源乳腺癌BT474裸鼠异种移植模型肿瘤生长产生抑制作用，且裸鼠耐受性良好。

关键词: 乳腺肿瘤, KU004, 乳腺癌BT474细胞, 异种移植, 裸鼠, 动物模型

Abstract:

Objective  To investigate the inhibitory effect of KU004 in human breast cancer BT474 nude mouse xenograft model.Methods 60 female BALB/c nude mice were inoculated with human breast cancer BT474 cells，and 40 with tumor growth to 100 -160 mm3 were randomly divided into 5 groups（n=8）；they were gavaged with 40，80，or 120 mg/kg KU004；80 mg/kg lapatinib or 0.5% hydroxypropyl methylcellulose solution respectively，once a day for 21 days. Before and 1，4，7，11，14，17，21 days after the adminis-tration，tumor volume and weight were measured in all 5 groups，and relative tumor growth rate（T/C） and tumor inhibition rate （IR） were calculated. Results  Human breast cancer BT474 nude mouse xenograft model was successfully established. The tumor weight in lapatinib， high-， medium- and low-dose KU004 groups had little change，but there was no significant difference when compared with the model group（P＞0.05）. The TV and RTV of each drug-administered group were significantly lower than that in the model group （P＜0.01），while there was no significant difference between the lapatinib group and the KU004 medium-dose group （P>0.05）. The T/C in lapatinib group， high-，mid-，and low-dose KU004 group  gradually decreased，and T/C was 15.6%，6.9%，11.4%，and 32.7% at 21 days，and IR was 85.0%，95.0%，91.0%，and 67.0%，respectively. Conclusions KU004 in high-，mid-，and low dose can inhibit the tumor growth of human breast cancer BT474 xenograft model，and the nude mice can tolerate well.

Key words: Breast neoplasms, KU004, Breast cancer BT474 cells, Xenograft, Nude mouse, Animal model